Table 4.
Variables | Total N |
Died N |
Died % |
Model 1 | Model 2 | Model 2 | |||
---|---|---|---|---|---|---|---|---|---|
OR | 95% CI | OR | 95% CI | OR | 95% CI | ||||
Calendar year | 6,113 | 267 | 4.4 | 0.9 | 0.9 to 1.03 | 0.94 | 0.90 to 0.99 | 0.94 | 0.90 to 0.99 |
CCI | |||||||||
0 | 2,797 | 27 | 1.0 | – | – | – | – | – | – |
1 | 1,372 | 36 | 2.6 | 2.49 | 1.50 to 4.14 | 2.07 | 1.22 to 3.50 | 2.05 | 1.21 to 3.48 |
2 | 360 | 14 | 3.9 | 3.40 | 1.75 to 6.60 | 2.70 | 1.34 to 5.43 | 2.67 | 1.32 to 5.39 |
≥3 | 1,584 | 190 | 12.0 | 13.15 | 8.70 to 19.89 | 4.98 | 2.97 to 8.33 | 4.92 | 2.93 to 8.26 |
Age (years) | |||||||||
<40 | 1,140 | 28 | 2.5 | – | – | – | – | – | – |
40 to 49 | 2,235 | 74 | 3.3 | 1.24 | 0.79 to 1.94 | 1.28 | 0.79 to 2.07 | 1.28 | 0.79 to 2.09 |
50 to 59 | 1,871 | 98 | 5.2 | 1.75 | 1.12 to 2.72 | 1.83 | 1.14 to 2.95 | 1.84 | 1.14 to 2.97 |
≥60 | 867 | 67 | 7.7 | 2.86 | 1.79 to 4.58 | 3.16 | 1.91 to 5.24 | 3.18 | 1.92 to 5.30 |
Sex | |||||||||
Male | 4,208 | 188 | 4.5 | – | – | – | – | – | – |
Female | 1,905 | 79 | 4.1 | 0.91 | 0.69 to 1.20 | 0.92 | 0.68 to 1.24 | 0.91 | 0.68 to 1.23 |
Ethnicity | |||||||||
Non-Hispanic White | 5,042 | 232 | 4.6 | – | – | – | – | – | – |
Non-Hispanic Blacks | 746 | 14 | 1.9 | 0.38 | 0.22 to 0.66 | 0.35 | 0.19 to 0.63 | 0.35 | 0.20 to 0.64 |
Other | 325 | 21 | 6.5 | 1.58 | 0.97 to 2.56 | 1.49 | 0.88 to 2.52 | 1.49 | 0.88 to 2.51 |
GI bleeding | |||||||||
Negative | 5,549 | 201 | 3.6 | – | – | – | – | – | – |
Present | 564 | 66 | 11.7 | 1.85 | 1.31 to 2.62 | 1.85 | 1.30 to 2.62 | ||
Encephalopathy | |||||||||
Negative | 5,460 | 168 | 3.1 | – | – | – | – | – | – |
Present | 653 | 99 | 15.2 | 1.54 | 1.09 to 2.18 | 1.54 | 1.09 to 2.18 | ||
HRS | |||||||||
Negative | 5,960 | 212 | 3.6 | – | – | – | – | – | – |
Present | 153 | 55 | 35.9 | 5.11 | 3.36 to 7.75 | 5.05 | 3.32 to 7.70 | ||
Pancreatitis | |||||||||
Negative | 5,206 | 245 | 4.7 | – | – | – | – | – | – |
Positive | 907 | 22 | 2.4 | 0.96 | 0.59 to 1.56 | 0.96 | 0.59 to 1.56 | ||
Sepsis | |||||||||
Negative | 5,925 | 200 | 3.4 | – | – | – | – | – | – |
Positive | 188 | 67 | 35.6 | 9.07 | 6.14 to 13.38 | 9.02 | 6.11 to 13.34 | ||
HCV | |||||||||
Negative | 5,548 | 240 | 4.3 | – | – | – | – | – | – |
Positive | 565 | 27 | 4.8 | 0.76 | 0.48 to 1.21 | 0.76 | 0.48 to 1.21 | ||
Hepatocellular carcinoma | |||||||||
Negative | 6,077 | 257 | 4.2 | – | – | – | – | – | – |
Positive | 36 | 10 | 27.8 | 3.92 | 1.63 to 9.42 | 3.95 | 1.64 to 9.48 | ||
Cirrhosis | |||||||||
Negative | 4,384 | 105 | 2.4 | – | – | – | – | – | – |
Positive | 1,729 | 162 | 9.4 | 1.35 | 0.99 to 1.85 | 1.35 | 0.99 to 1.85 | ||
Medication use | |||||||||
Negative | 5,411 | 206 | 3.8 | – | – | – | – | – | – |
Pentoxifylline | 539 | 41 | 7.6 | 1.16 | 0.56 to 2.40 | ||||
Corticosteroid | 103 | 12 | 11.7 | 1.06 | 0.71 to 1.56 | ||||
Both | 60 | 8 | 13.3 | 1.03 | 0.39 to 2.68 |
Charleson Comorbidity Index; GI, gastrointestinal; HCV, hepatitis C virus; HRS, hepatorenal syndrome.